Exercise during combined radiotherapy and chemotherapy for stage II–III non-small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a feasibility study of a supervised, multimodal exercise program delivered throughout concurrent chemoradiotherapy for unresectable stage II–III non‑small cell lung cancer. The program is tailored to each patient and includes inspiratory muscle training, moderate‑intensity aerobic exercise, and strength work, with sessions supervised at the hospital. Primary outcomes focus on safety and adherence, while secondary measures explore changes in physical fitness, respiratory function, and quality of life. Participants are recruited at two Spanish centers and those with severe unstable cardiac or pulmonary comorbidities are excluded.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histological diagnosis of non-small cell lung cancer (NSCLC) at stage II-III (locally advanced), unresectable/inoperable.
* Candidate for radical radiotherapy with concomitant chemotherapy, with or without maintenance Durvalumab.
* ECOG performance status ≤2 (or Karnofsky index ≥60).
* Ability to communicate adequately with the research team and to complete questionnaires and functional tests.
* Signed written informed consent after receiving detailed information about the study.

Exclusion Criteria:

* Decompensated cardiorespiratory comorbidities that contraindicate moderate-intensity physical exercise:

  * New York Heart Association (NYHA) class III-IV congestive heart failure or unstable angina.
  * Recent myocardial infarction (\<6 months) or uncontrolled arrhythmias.
  * Very severe chronic obstructive pulmonary disease (COPD) GOLD IV with recent exacerbations, permanent home oxygen therapy, or severe pulmonary hypertension.
* Severe physical or neurological limitations that prevent exercise.
* Absolute medical contraindications to inspiratory muscle training: unresolved pneumothorax, recent thoracic surgery (\<4 weeks), or active hemoptysis.
* Refusal or inability to understand/follow the program instructions (e.g., severe cognitive impairment, insurmountable language barrier).

Where it's running

• Hospital Clinic de Barcelona
  Barcelona, Catalonia, Spain Recruiting
• Hospital Universitario de Navarra
  Pamplona, Navarre, Spain Recruiting

Study contacts

• Study coordinator: Jurgi Zulaika
• Email: jurgi.zulaika@deusto.es
• Phone: +34 943 32 66 00

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery

  This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07837739

• HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC

  This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Wuhan, Hubei · NCT07824882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.